CELEBREX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Celebrex, and what generic alternatives are available?
Celebrex is a drug marketed by Upjohn and is included in one NDA.
The generic ingredient in CELEBREX is celecoxib. There are twenty-six drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the celecoxib profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Celebrex
A generic version of CELEBREX was approved as celecoxib by TEVA on May 30th, 2014.
Summary for CELEBREX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 175 |
Clinical Trials: | 236 |
Patent Applications: | 5,125 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CELEBREX |
Drug Sales Revenues: | Drug sales revenues for CELEBREX |
What excipients (inactive ingredients) are in CELEBREX? | CELEBREX excipients list |
DailyMed Link: | CELEBREX at DailyMed |
Recent Clinical Trials for CELEBREX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Henry Ford Health System | Phase 4 |
Atriva Therapeutics GmbH | Phase 1 |
United States Army Research Institute of Environmental Medicine | Phase 1 |
Pharmacology for CELEBREX
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for CELEBREX
US Patents and Regulatory Information for CELEBREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-004 | Dec 15, 2006 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-003 | Aug 29, 2002 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-001 | Dec 31, 1998 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CELEBREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-001 | Dec 31, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-001 | Dec 31, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-004 | Dec 15, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for CELEBREX
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Limited | Onsenal | celecoxib | EMEA/H/C/000466 Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1) |
Withdrawn | no | no | no | 2003-10-17 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for CELEBREX
See the table below for patents covering CELEBREX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 3025017 | ⤷ Try a Trial | |
European Patent Office | 0924201 | Pyrazolyl-benzènesulfonamides tricycliques substitués utilisés comme inhibiteurs de la cyclooxygénase-2 (Tricyclic-substituted pyrazolyl benzenesulfonamides and their use as cyclooxygenase II inhibitors) | ⤷ Try a Trial |
South Korea | 100263817 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CELEBREX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0731795 | CA 2009 00005 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MAVACOXIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF |
0731795 | 122009000012 | Germany | ⤷ Try a Trial | PRODUCT NAME: MAVACOXIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/2/08/084/001-005 20080909 |
0731795 | SZ 4/2009 | Austria | ⤷ Try a Trial | PRODUCT NAME: MAVACOXIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |